StemCells, Inc. (STEM) on Thursday announced the initiation of a Phase I/II clinical trial of the company's proprietary HuCNS-SC product candidate (purified human neural stem cells) in dry age-related macular degeneration or AMD referred to as Geographic Atrophy.
Dry AMD is the most common form of macular degeneration. There are no approved treatments for the condition.
The trial is being conducted at the Retina Foundation of the Southwest's Anderson Vision Research Center in Dallas, Texas.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.